OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.
Visit go.covermymeds.com/OptumRx to begin using this free service.
Please note: All information below is required to process this request.
Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Opdivo® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)

Member Name:		
Insurance ID#:		
Date of Birth:		
Street Address:		
City:	State:	Zip:
Phone:		

Provider Information (required)

Provider Name:		
NPI#:	Specialty:	
Office Phone:		
Office Fax:		
Office Street Address:		
City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

- ❑ Classical Hodgkin lymphoma (cHL)
- ❑ Colorectal cancer
- ❑ Head and neck squamous cell carcinoma (HNSCC)
- ❑ Hepatocellular carcinoma
- ❑ Melanoma
- ❑ Non-small cell lung cancer (NSCLC)
- ❑ Renal cell carcinoma
- ❑ Small cell lung cancer
- ❑ Urothelial carcinoma
- ❑ Other diagnosis: _____ ICD-10 Code(s): _____

Prescriber's Specialty:

Is Opdivo prescribed by or in consultation with an oncologist? ❑ **Yes** ❑ **No**

For classical Hodgkin lymphoma (cHL), answer the following:

Has the patient had relapse or progression after autologous hematopoietic stem cell transplantation (HSCT)? ❑ **Yes** ❑ **No**
Has the patient had relapse or progression with Adcetris (brentuximab vedotin) treatment? ❑ **Yes** ❑ **No**
Has the patient had relapse or progression after three or more lines of systemic therapy that includes autologous HSCT? ❑ **Yes** ❑ **No**

For colorectal cancer, answer the following:

Does the patient have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer? ❑ **Yes** ❑ **No**
Has the patient experienced disease progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan? ❑ **Yes** ❑ **No**

For head and neck squamous cell carcinoma (HNSCC), answer the following:

Does the patient have recurrent disease? ❑ **Yes** ❑ **No**
Does the patient have metastatic disease? ❑ **Yes** ❑ **No**
Has the patient experienced disease progression on or after platinum-based chemotherapy (e.g., cisplatin, carboplatin)? ❑ **Yes** ❑ **No**

For hepatocellular carcinoma (HCC), answer the following:

Was the patient previously treated with Nexavar (sorafenib)? ❑ **Yes** ❑ **No**

Opdivo® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For melanoma, answer the following:

Does the patient have unresectable disease? ❑ **Yes** ❑ **No**

Does the patient have metastatic disease? ❑ **Yes** ❑ **No**

Will Opdivo be used in the adjuvant setting following complete resection of Stage IIIB/C (lymph node involvement) or Stage IV (metastatic) disease? ❑ **Yes** ❑ **No**

For non-small cell lung cancer (NSCLC), answer the following:

Does the patient have metastatic disease? ❑ **Yes** ❑ **No**

Has the patient experienced disease progression on or after platinum-based chemotherapy (e.g., cisplatin, carboplatin)? ❑ **Yes** ❑ **No**

Does the patient have epidermal growth factor receptor (EGFR) genomic tumor aberrations? ❑ **Yes** ❑ **No**

If "yes" to the above question, has the patient experienced disease progression on one anti-EGFR therapy (e.g., Gilotrif [afatinib], Iressa [gefitinib], Tarceva [erlotinib])? ❑ **Yes** ❑ **No**

Does the patient have anaplastic lymphoma kinase (ALK) genomic tumor aberrations? ❑ **Yes** ❑ **No**

If "yes" to the above question, has the patient experienced disease progression on one ALK inhibitor (e.g., Alecensa [alectinib], Xalkori [crizotinib], Zykadia [ceritinib])? ❑ **Yes** ❑ **No**

For renal cell carcinoma, answer the following:

Does the patient have advanced, relapsed, or stage IV disease? ❑ **Yes** ❑ **No**

Does the patient have surgically unresectable disease? ❑ **Yes** ❑ **No**

Has the patient received prior anti-angiogenic therapy (e.g., Inlyta [axitinib], Votrient [pazopanib], Sutent [sunitinib], Nexavar [sorafenib])? ❑ **Yes** ❑ **No**

Does the patient have intermediate- or poor-prognosis risk? ❑ **Yes** ❑ **No**

Was the patient previously untreated? ❑ **Yes** ❑ **No**

Will Opdivo be used in combination with Yervoy (ipilimumab)? ❑ **Yes** ❑ **No**

For small cell lung cancer, answer the following:

Does the patient have metastatic disease? ❑ **Yes** ❑ **No**

Has the patient experienced progression after platinum-based therapy and at least one other therapy? ❑ **Yes** ❑ **No**

For urothelial carcinoma, answer the following:

Does the patient have locally advanced disease? ❑ **Yes** ❑ **No**

Does the patient have metastatic disease? ❑ **Yes** ❑ **No**

Has the patient experienced disease progression during or following platinum-based chemotherapy? ❑ **Yes** ❑ **No**

Has the patient experienced disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy? ❑ **Yes** ❑ **No**

Reauthorization:

Does the patient show evidence of disease progression while on Opdivo therapy? ❑ **Yes** ❑ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.